The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series
One of the main causes of death in COVID-19 is the dysregulation of the host’s immune system which leads to cytokine storm, a potentially fatal systemic inflammatory syndrome. Interleukin 6 (IL-6) is a pro-inflammatory cytokine that is produced in response to infections and tissue injuries and is be...
Saved in:
Main Authors: | Eric Daniel Tenda, Setiabakti Andrian, Sedjahtera Albert, Moses M Asaf, Ceva W Pitoyo, Siti Setiati, Imam Subekti |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2021-10-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/1854 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01) -
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01) -
Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis
by: M. M. Kostik, et al.
Published: (2013-09-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)